環球醫療(02666.HK)附屬就成立合資公司與西昌新鋼業簽訂合作協議
格隆匯 1 月 25日丨環球醫療(02666.HK)發佈公吿,有關攀鋼集團總醫院及攀鋼集團成都醫院的重組。2021年1月25日,公司全資附屬公司醫投公司與西昌新鋼業簽訂合作協議,內容有關成立一家合資公司。根據合作協議,合資公司的總投資約為人民幣3.459億元,其中醫投公司將以現金投入人民幣1.764億元,西昌新鋼業將以目標公司(凉山州攀新健康管理有限公司,為攀鋼西昌醫院舉辦人)100%股權投入人民幣1.695億元。該交易一經完成,合資公司的註冊資本將分別由醫投公司持有51%,由西昌新鋼業持有49%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.